Takeda to Present Rare Bleeding Disorders Research Highlighting Need for Real-World Evidence at NHF Bleeding Disorders Conference 2020

Nachrichtenquelle: Business Wire (engl.)
01.08.2020, 17:00  |  143   |   |   

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”), today presented three abstracts at the 72nd National Hemophilia Foundation’s Bleeding Disorders Conference, underscoring the need for real-world evidence (RWE) to advance patient-centric treatment in bleeding disorders.

RWE from these studies highlight the ongoing unmet clinical need for diagnosis, personalization and treatment optimization in patients with hemophilia and von Willebrand’s disease (VWD). Takeda’s presence at NHF Bleeding Disorders Conference includes the following presentations, which are intended for scientific discussion only:

Hemophilia A and B

  • Adding the patient’s voice to a hemophilia specific goal menu to facilitate Goal Attainment Scaling: a qualitative study
    • Many outcome measures in hemophilia lack sensitivity, and few are patient centric. A refined Goal-Hēm hemophilia-specific goal menu was evaluated by patients with hemophilia to determine relevancy to the challenges they face. Participants endorsed the clarity and relevance of the revised menu and expressed enthusiasm for further interaction with the tool. Patient-centered tools such as this have the potential to detect clinically meaningful changes for both clinicians and individuals affected by hemophilia, while improving patient outcomes.1
  • Incidence and prevalence of diagnosed and undiagnosed hemophilia A and hemophilia B in the USA
    • This study highlights the thousands of patients remaining undiagnosed in the US and the need for improvement in diagnosis and/or reporting.2

Von Willebrand Disease

  • Analysis of Bleeding and Treatment Patterns in Children and Adolescents before and after von Willebrand Disease Diagnosis Using Data from a US Medical Claims Database
    • This abstract underscores US medical claims data that characterize the diagnosis, bleeding and treatment patterns in children and adolescents with VWD and points to the need for improved treatment and care of this patient population.3

“Real-world evidence plays a crucial role in understanding patterns of care and the patient’s holistic experience outside of rigorous clinical studies,” said Michael Denne, VP of Medical Affairs, Hematology Rare Disease Unit at Takeda Pharmaceuticals. “Takeda is a passionate patient advocate and is working to provide critically-important personalized support that helps ensure that patients find, and remain on, the right therapy. These data highlight the gaps in diagnosis and treatment still prevalent in the bleeding disorders community today, and spotlight opportunities for Takeda to better support these patients.”

Seite 1 von 5
Takeda Yakuhin Kogyo Aktie jetzt ab 0€ handeln - auf Smartbroker.de

Diesen Artikel teilen

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren



Meistgelesene Nachrichten des Autors